Unique ID issued by UMIN | UMIN000038103 |
---|---|
Receipt number | R000043418 |
Scientific Title | Sodium-glucose cotransporter 2 inhibition reduces body weight but not plasma glucose level in patients with type2 diabetes and mild renal failure |
Date of disclosure of the study information | 2019/09/26 |
Last modified on | 2019/09/26 09:45:56 |
Sodium-glucose cotransporter 2 inhibition reduces body weight but not plasma glucose level in patients with type2 diabetes and mild renal failure
Sodium-glucose cotransporter 2 inhibition reduces body weight but not plasma glucose level in patients with type2 diabetes and mild renal failure
Sodium-glucose cotransporter 2 inhibition reduces body weight but not plasma glucose level in patients with type2 diabetes and mild renal failure
Sodium-glucose cotransporter 2 inhibition reduces body weight but not plasma glucose level in patients with type2 diabetes and mild renal failure
Japan |
type2 diabetes
Endocrinology and Metabolism |
Others
NO
In this study, SGLT 2 inhibitor was administered and the effectiveness to reduce body weight was examined, not to lower the blood glucose level of type 2 diabetic patients with mild renal failure.
Efficacy
Exploratory
Pragmatic
Not applicable
HbA1c and body weight
We compared eGFR> 60 with normal kidney function, eGFR <60 as mild renal failure and comparing changes in body weight change with the two groups of HbA1c.
Observational
20 | years-old | <= |
85 | years-old | > |
Male and Female
1) Outpatients
2) over 20 years old
3) T2DM
4) eGFR over 15 mL/min/1.73 m2
5) Diet and exercise therapies are well performed
6) Patients who are suspected good-compliant
7) Understanding of the study procedures and agreement to participate in the study
1) Patients suspected of having secondary diabetes (ex. endocrine disease, drug-induced or liver disease)
2) Females who are pregnant or who intend to become pregnant within the study
3) Severe hepatic disease, malignancy, a history of gastrectomy and/or positive for HIV
4) Contraindication with SGLT2 inhibitors
5) Patient who disqualified from the study by the investigator for any reason other than given above.
50
1st name | Shinji |
Middle name | |
Last name | Taneda |
Manda Memorial Hospital
Diabetes Center
060-0062
Minami 2, Nishi 1, Chuo-ku, Sapporo
011-231-4032
taneda@manda.or.jp
1st name | Yasuhiro |
Middle name | |
Last name | Iijima |
Manda Memorial Hospital
Diabetes Center
060-0062
Minami 2, Nishi 1, Chuo-ku, Sapporo
011-231-4032
yasuhiro.iijima1203@gmail.com
Manda Memorial Hospital
none
Self funding
Manda Memorial Hospital
Minami 2, Nishi 1, Chuo-ku, Sapporo
011-231-4032
taneda@manda.or.jp
NO
萬田記念病院(北海道)
2019 | Year | 09 | Month | 26 | Day |
Unpublished
80
Completed
2018 | Year | 04 | Month | 01 | Day |
2018 | Year | 10 | Month | 28 | Day |
2018 | Year | 10 | Month | 28 | Day |
2019 | Year | 04 | Month | 01 | Day |
none
2019 | Year | 09 | Month | 26 | Day |
2019 | Year | 09 | Month | 26 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000043418
Research Plan | |
---|---|
Registered date | File name |
Research case data specifications | |
---|---|
Registered date | File name |
Research case data | |
---|---|
Registered date | File name |